Literature DB >> 26208318

Cancer death rates in US congressional districts.

Rebecca L Siegel1, Liora Sahar2, Kenneth M Portier3, Elizabeth M Ward4, Ahmedin Jemal5.   

Abstract

Knowledge of the cancer burden is important for informing and advocating cancer prevention and control. Mortality data are readily available for states and counties, but not for congressional districts, from which representatives are elected and which may be more influential in compelling legislation and policy. The authors calculated average annual cancer death rates during 2002 to 2011 for each of the 435 congressional districts using mortality data from the National Center for Health Statistics and population estimates from the US Census Bureau. Age-standardized death rates were mapped for all sites combined and separately for cancers of the lung and bronchus, colorectum, breast, and prostate by race/ethnicity and sex. Overall cancer death rates vary by almost 2-fold and are generally lowest in Mountain states and highest in Appalachia and areas of the South. The distribution is similar for lung and colorectal cancers, with the lowest rates consistently noted in districts in Utah. However, for breast and prostate cancers, while the highest rates are again scattered throughout the South, the geographic pattern is less clear and the lowest rates are in Hawaii and southern Texas and Florida. Within-state heterogeneity is limited, particularly for men, with the exceptions of Texas, Georgia, and Florida. Patterns also vary by race/ethnicity. For example, the highest prostate cancer death rates are in the West and north central United States among non-Hispanic whites, but in the deep South among African Americans. Hispanics have the lowest rates except for colorectal cancer in Wyoming, eastern Colorado, and northern New Mexico. These data can facilitate cancer control and stimulate conversation about the relationship between cancer and policies that influence access to health care and the prevalence of behavioral and environmental risk factors.
© 2015 American Cancer Society.

Entities:  

Keywords:  Congress; cancer mortality; geography; legislation

Mesh:

Year:  2015        PMID: 26208318     DOI: 10.3322/caac.21292

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  28 in total

1.  Lanthanides: Applications in Cancer Diagnosis and Therapy.

Authors:  Ruijie D Teo; John Termini; Harry B Gray
Journal:  J Med Chem       Date:  2016-02-19       Impact factor: 7.446

2.  Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.

Authors:  Anna Katharina Seitz; Isabel Rauscher; Bernhard Haller; Markus Krönke; Sophia Luther; Matthias M Heck; Thomas Horn; Jürgen E Gschwend; Markus Schwaiger; Matthias Eiber; Tobias Maurer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-28       Impact factor: 9.236

Review 3.  Brain metastasis in lung cancer: Building a molecular and systems-level understanding to improve outcomes.

Authors:  Johnathan D Ebben; Ming You
Journal:  Int J Biochem Cell Biol       Date:  2016-07-27       Impact factor: 5.085

Review 4.  Role of steroid receptor and coregulator mutations in hormone-dependent cancers.

Authors:  Anna C Groner; Myles Brown
Journal:  J Clin Invest       Date:  2017-04-03       Impact factor: 14.808

5.  Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.

Authors:  Xi Tan; Fabian Camacho; Vincent D Marshall; Joseph Donohoe; Roger T Anderson; Rajesh Balkrishnan
Journal:  Res Social Adm Pharm       Date:  2016-08-25

6.  Racial/Ethnic Disparities in Prostate Cancer Incidence, Distant Stage Diagnosis, and Mortality by U.S. Census Region and Age Group, 2012-2015.

Authors:  Siddharth Iyengar; Ingrid J Hall; Susan A Sabatino
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-17       Impact factor: 4.254

7.  Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.

Authors:  Etay Ziv; Joseph P Erinjeri; Hooman Yarmohammadi; F Edward Boas; Elena N Petre; Song Gao; Waleed Shady; Constantinos T Sofocleous; David R Jones; Charles M Rudin; Stephen B Solomon
Journal:  Radiology       Date:  2016-07-19       Impact factor: 11.105

8.  Influence of a single-nucleotide polymorphism of the DNA mismatch repair-related gene exonuclease-1 (rs9350) with prostate cancer risk among Chinese people.

Authors:  Yiming Zhang; Pengju Li; Abai Xu; Jie Chen; Chao Ma; Akiko Sakai; Liping Xie; Lei Wang; Yanqun Na; Haruki Kaku; Peng Xu; Zhong Jin; Xiezhao Li; Kai Guo; Haiyan Shen; Shaobo Zheng; Hiromi Kumon; Chunxiao Liu; Peng Huang
Journal:  Tumour Biol       Date:  2015-12-08

9.  A Self-Folding Hydrogel In Vitro Model for Ductal Carcinoma.

Authors:  Hye Rin Kwag; Janna V Serbo; Preethi Korangath; Saraswati Sukumar; Lewis H Romer; David H Gracias
Journal:  Tissue Eng Part C Methods       Date:  2016-03-16       Impact factor: 3.056

10.  Mortality-to-incidence ratios by US Congressional District: Implications for epidemiologic, dissemination and implementation research, and public health policy.

Authors:  Jan M Eberth; Whitney E Zahnd; Swann Arp Adams; Daniela B Friedman; Stephanie B Wheeler; James R Hébert
Journal:  Prev Med       Date:  2019-11-01       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.